Webb David John
Queen's Medical Research Institute, The University of Edinburgh, Room E3.22, Edinburgh EH16 4TJ, UK.
Br J Clin Pharmacol. 2012 Jun;73(6):874-7. doi: 10.1111/j.1365-2125.2012.04228.x.
Clinical pharmacologists in universities play major roles in research and teaching and provide important contributions to National Health Service (NHS) activities, such as work for research ethics, drug and therapeutics, and clinical governance committees. Their research extends from preclinical studies using drugs to understand physiology and the mechanisms of disease to large-scale clinical trials and population studies. This work is truly translational, with a focus on drugs and medicines and an emphasis on efficacy and safety. The lack of an organ base has allowed clinical pharmacologists to follow their interests wherever they lead, but their visibility has been hampered by successive earlier versions of the General Medical Council's Tomorrow's Doctors document, which undermined some of the necessary scientific underpinning of medical practice and reduced the time clinical pharmacologists had to interact with medical students and recently qualified doctors at the point of choosing their careers. Additional problems have arisen from the stifling effect of the European Union Clinical Trials Directive, and its UK interpretation, on clinical research. For future success, clinical pharmacologists need to embrace translational research, use recent changes to Tomorrow's Doctors, linked to the creation of safe prescribing skills, to spend more face-to-face time with their students, fight for a simplification and proportionate regulation of research, and persuade doctors, health service planners and the government of the importance of clinical pharmacology for UK clinical research, the NHS, patient safety and creation of health and wealth.
大学临床药理学家在研究和教学中发挥着重要作用,并为国民医疗服务体系(NHS)的活动做出重要贡献,比如参与研究伦理、药物与治疗学以及临床治理委员会的工作。他们的研究范围从使用药物的临床前研究,以了解生理学和疾病机制,到大规模临床试验和人群研究。这项工作具有真正的转化性,专注于药物和药品,并强调疗效和安全性。缺乏一个专门的机构基础使得临床药理学家能够追随自己的兴趣,但他们的知名度却受到了英国医学总会(General Medical Council)早期版本的《明日医生》文件的影响,该文件削弱了医疗实践的一些必要科学基础,并减少了临床药理学家在医学生和刚获得资格的医生选择职业时与其互动的时间。欧盟临床试验指令及其在英国的解读对临床研究产生的抑制作用也引发了其他问题。为了未来的成功,临床药理学家需要接受转化研究,利用与安全处方技能培养相关的《明日医生》的最新变化,与学生有更多面对面交流的时间,争取简化并适度规范研究,并向医生、医疗服务规划者和政府说明临床药理学对英国临床研究、国民医疗服务体系、患者安全以及健康与财富创造的重要性。